DPCP plus immunotherapy for skin cancer spread to the skin
Part of Cancer, Skin clinical trials.
This Phase 1 study tests a skin-applied treatment called DPCP added to standard PD-1/PD-L1 immunotherapy for cancers that have spread to the skin. It aims to improve control of skin tumors while checking safety and how well the immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have cancer that has spread to your skin in at least three spots that can be biopsied
- Your cancer doctor plans to treat you with an FDA-approved PD-1 or PD-L1 immune therapy (even if you join the study)
- You can get through the study with good day-to-day function (ECOG 0 to 2)
- You can have the study team take informed consent, and you’re able/willing to sign it
- If you can become pregnant: you’re not pregnant and you’ll use reliable birth control during the study and for 90 days after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
This study looks at whether a blood test called D-dimer can predict how well cemiplimab (an immunotherapy drug) works for advanced skin cancer. If you are already planning to get cemiplimab, the study will collect your D-dimer results and follow your progress to see if the test helps guide treatment.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This early-phase study tests an anti–PD-1 antibody, either alone or with decitabine or chemotherapy, in people whose cancer has come back or isn’t responding to treatment. It may help your immune system attack the cancer, especially after prior therapies.
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
Hear when a new Cutaneous Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.